HTAi: A Global Collaboration - hta-rus.ru · 3.HTAi and global collaboration in HTA 4.Final thoughts. Why a Global Collaboration in HTA?: 1rst Innovation Shifting paradigm at any

HTAi: A Global Collaboration Laura Sampietro-Colom, MD, PhD

Deputy Director Innovation. Hospital Clinic Barcelona

HTAi Immediate Past President

Index

1.Why a Global Collaboration in HTA?

2.What HTAi is?

3.HTAi and global collaboration in HTA

4.Final thoughts

Why a Global Collaboration in HTA?: 1rst

Shifting paradigmInnovation at any price

Innovation at value based reimbursement/price

“ You may consider yourself an individual, but I can tell

you that you are in a truth a cooperative community of

approximately fifty trillion single-celled citizens. Almost all

of your cells that make up your body are amoeba-like,

individual organisms that have evolved a cooperative

strategy for their mutual survival”

Lipthon B H, PhD (Cell biologists).

The Biology of Believe. 2008

Why a Global Collaboration in HTA?: 2nd

Survival depends on cooperation/ collaboration

Why a Global Collaboration?: 3rd

NETWORKS

META-

NETWORKS

Globalize Knowledge

Localize decisions

• Regulatory agencies

• Governments

• Payers

• Providers

• Industry

• Patients

• Safety/efficacy/effectiveness

• Access to services

• Profitability

• High quality

• Cost containment

• Convenience

• Patient centeredness

• Satisfaction

Many stakeholders

Conflicting goals and incentives

Why a Global Collaboration?: 3rd

Localize decisions

1. The only interdisciplinar

international scientific &

professional society focusing

specifically in HTA

Meeting point

Building Together

What HTAi is?

2. Scientific & health care

policy science for

appropriate HT access and

use

Network

What HTAi is?

3. Network for

Global thinking –

HTA diffusion &

Local action

Individuals

National/Federal Governments

Regional Governments

Insurance Companies

HealthTech industry

Hospitals

Primary care

HTA Agencies

What HTAi is?

• 52 Not-for-profit organizational members

• 16 For-profit organizational members

# of members/continent

Africa 7

Asia 86

Oceania 56

Europe 380

North America 222

South America 588

TOTAL MEMBERS 1339

HTAi:

The Scientific & Professional Society

HTAi:


Privat

Canada

U.S.A

Non-for-Profit Organizational Members = 52

HTAi:


http://www.icer-review.org/

http://www.nlm.nih.gov/

http://www.path-hta.ca/

http://www.blueshieldcafoundation.org/

U.K.

Germany

Spain

Non-for-Profit Organizational Members

HTAi:


http://www.osanet.euskadi.net/osteba/es

http://www.iqwig.de/

http://www.dimdi.de/dynamic/en/index.html

http://www.juntadeandalucia.es/salud/orgdep/aetsa/

http://www.hta.ac.uk/

http://www.sheffield.ac.uk/

Other European countries

HTAi:



SPC on Standardization and HTA

http://www.stakes.fi/finohta/

http://www.cvz.nl/

http://www.aotm.gov.pl/index.php



http://www.sst.dk/




http://www.sbu.se/

http://www.sukl.sk/en?page_id=256

http://www.santesuisse.ch/de/dyn_output.html?content.vname=portal

Australia and New Zealand

Asia

HTAi:






http://www.ha.org.hk/visitor/ha_index.asp

http://www.health.qld.gov.au/

http://www.moh.gov.sg/mohcorp/default.aspx

http://www.singhealth.com.sg/

http://www.nhg.com.sg/index.asp

http://post.cre8ive.com.au/t/r-l-dktudkt-l-t/

Europe: Clustering National HTA organizations

by their role in the assessment process

Perform the assessment and recommend (others take

final decision) (eg. SBU, DACEHTA, HAS, Spanish National &

Regional Agencies)

Perform a section of assessment (but own final report),

commission some sections, and recommend (others

take final decision) (eg. IQWiG, DAHTA, UVKL)

Mainly commission all the assessments and takes

decisions on coverage (eg. G-BA, NICE (MTA), AWSMG,

AIFA)

Industry perform the assessment, institutions check

the quality (redo model if needed) (eg. CVZ-CHT, TVL, SMC,

NICE (STA))

Europe: Weight of Clinical & Economic

outcomes in final recommendation

G-BA

IQWiG

CVZ

HAS

INCA

AIFA (up to now)

Clinical

NICE, SMC, AWMSG

SBU, TVL

Spanish Institutions

Regions

NICE, SMC,

AWMSG

CVZ (orientative)

Europe: Looking at economics

QALY based CEA

NICE, SMC, AWMSG

CVZ-CHT *

TVL

AIFA (recently)

BIA

UVKL

GB-A

HAS

Regions DK, Italy, Spain, Sweden

Hospitals (all)

Primary Care Trusts (UK)

Other economics

IQWiG * (CEA, recently)

GB-A (CEA, recently)

DACEHTA (CEA)

HAS (post-assessment

added value,post

launch)

Always

* If new treatment show

clinical added value

Sometimes

SBU (CUA, CEA, BIA)

DAHTA (BIA)

Spanish and Italian Regions (CEA)

For-Profit Organizational Members = 16

HTAi:





http://www.astrazeneca.com/

http://www.abbott.com/

http://www.bayerhealthcare.com/scripts/pages/en/index.php

http://www.gsk.com/

http://en.sanofi-aventis.com/

http://www.genzyme.com/default.asp

1. Annual Meetings

• Travel grants for Low and Middle income countries to Annual Meeting

• Educational grants for LMIC

• “Jill Sanders” Scholarship (Africa)

2. Travel & Educational Grants

HTAi & Global Collaboration in HTA

3. Interest Subgroups

• Early Career Network (launched 2011) 99 members

• Conditional coverage/access with evidence 247 members

• HTA in developing countries 98 members

• Disinvestment of obsolete or low added value 93 members

technologies

• Ethics in HTAi 44 members

• Hospital-based HTA 96 members

• HTA Regulatory Interactions (launched 2012) 4 members

• Information resources 179 members

• Patient and citizen involvement in HTA 148 members


4. The web: www.htai.org


4.1. The web: Vortal


5.


6.

7. The Journal

Egon Jonson Award

for best paper


8. The HTAi Policy Forum– to facilitate productive interactions between

health care decision makers and industry

– to really bring industry, government and HTA

agencies working at the point of decision making

together.

– to have an open discussion of challenges so

that different perspectives and limitations can be

better understood


Born in 2005 in London

Members 2012: Non-for profit=14 / For profit=14

Chatham House Rule

“When a meeting, or part thereof, is held under the

Chatham House Rule, participants are free to use the

information received, but neither the identity nor the

affiliation of the speaker(s), nor that of any other

participant, may be revealed.”


8. The HTAi Policy Forum

8. The HTAi Policy Forum• Promoting Clinically Relevant Innovation and managing Uncertainty:

the role of the HTA process (6-7 Februry 2005, UK)

• Rethinking Regulation and HTA (5-7 February, 2006 Virginia, USA)

• Conditional Reimbursement / Coverage with Evidence (11-13 February

2007 , Zeist, Netherlands)

• Harmonizing Evidence Requirements for HTA in decision Making (10-12

February 2008, Rome, Italy)

• HTA for optimization of technology utilization (8-10 February, San

Francisco, USA)

• Managed Entry Schemes (31 January -2 February 2010, Washington

D.C., USA)

• HTA and Regulation (30 January-1 February 2011, London)

• HTA and disinvestment (San Francisco, 2012)


9. MoU

Pre-conference meeting (2011)

Participation in plenary (2011)

1. Annual Meeting (after HTAi)

2. Joint ISG

3. Bidirectional Communication

with members

1. First Global Forum on

Medical Devices (MD)

2. Call for Innovative MD

3. Workshops at HTAi meeting

4. Web-casting developing

countries

52 members

26 countries


ISG Emerging

Technologies

expected

10. HTA Glossary: HTAi, INAHTA, GIN, ISQUA

11. 1st Regional Meetings (LAC) (PAHO, Mercosur, MoH

Brazil and Argentina, IECS) (2010). 2nd expected 2012

12. Society for Medical Decision Making: Post-conference

½ day meeting (Nov. 2010), web-cast. Personalized

Medicine (2012)

13. Workshops with Regulatory Agencies (medicines and

Devices) (February & October 2011)


14. Workshops with MoH (Argentina 2010, PAHO 2010, China

2011)

15. Promoting presence of HTA International networks in HTAi

Annual Meetings (EUnetHTA, INAHTA, EuroScan)

• Friendly and open-mind space for networking: Cross-fertilization

• Robust grounded space for discussion of:

– HTA methods practices and

– Health policy science regarding HTs

– Ways to implement HTA results into systems and clinical practices

• Dynamic an interactive space for evolving the science of both methods and health policy for a wise promotion (innovative) and recall (obsolete) HTs.

• Neutral place of dialog between those who produce HTA, those responsible for HTA based coverage and health care practice decisions, and industry.

What can HTAi offer in a global world?

Final thoughts

• International/Global collaboration as an

imperative today

• Highly needed for survival and evolution

• Background of HTAi is to promote and foster

global collaboration

• If you want to be part of the global HTA

community, HTAi is your place!

Thank You!

HTAi: A Global Collaboration - hta-rus.ru · 3.HTAi and global collaboration in HTA 4.Final thoughts. Why a Global Collaboration in HTA?: 1rst Innovation Shifting paradigm at any

Documents